Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL154518 | 1.00 | LMNA (0.40) | LMNAALDH1A1L3MBTL1TDP1USP2 | |
| SCHEMBL27652464 | 0.85 | LMNA (0.46) | LMNAALDH1A1L3MBTL1TDP1USP2 | |
| SCHEMBL283453 | 0.81 | TDP1 (0.52) | LMNAALDH1A1L3MBTL1TDP1USP2 | |
| SCHEMBL5565943 | 0.81 | TDP1 (0.52) | LMNAALDH1A1L3MBTL1TDP1USP2 | |
| SCHEMBL24571155 | 0.78 | LMNA (0.33) | LMNAL3MBTL1TDP1 | |
| SCHEMBL10987335 | 0.77 | TDP1 (0.43) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL16478004 | 0.77 | TDP1 (0.43) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL23630292 | 0.77 | LMNA (0.38) | LMNAALDH1A1TDP1USP2THRB | |
| SCHEMBL21136347 | 0.75 | LMNA (0.36) | LMNAALDH1A1L3MBTL1TDP1USP2 | |
| SCHEMBL28435980 | 0.75 | LMNA (0.36) | LMNAALDH1A1USP2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258046-A1 | MANNOSE-CONTAINING SOLUTION FOR LYOPHILIZATION, TRANSFECTION AND/OR INJECTION OF NUCLEIC ACIDS | CureVac SE (DE) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258046-A1 | MANNOSE-CONTAINING SOLUTION FOR LYOPHILIZATION, TRANSFECTION AND/OR INJECTION OF NUCLEIC ACIDS | M6PR, MAN2A1, MPI | LMNA 329/4885ALDH1A1 4144/4885L3MBTL1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.